Hyperthermia enhances the cytotoxicity and platinum-DNA adduct formation of lobaplatin and oxaliplatin in cultured SW 1573 cells

Journal of Cancer Research and Clinical Oncology

Volumn 123, Issue 1, 1997, Pages 6-12

  Rietbroek, R C ^a   Van De Vaart, P J M ^c   Haveman, J ^b   Blommaert, F A ^c   Geerdink, A ^b   Bakker, P J M ^a   Veenhof, C H N ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Cisplatin; Cytotoxicity; Hyperthermia, induced; Lobaplatin; Oxaliplatin; Platinum DNA adduct formation

Indexed keywords

CISPLATIN; LABOPLATIN; OXALIPLATIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DNA ADDUCT; HUMAN; HUMAN CELL; HYPERTHERMIA; LUNG SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; TUMOR CELL;

EID: 0031060553     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01212608     Document Type: Article

References (40)

1. Barlogie B, Corry PM, Drewinko B (1980) In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammine-platinum(II) and mitomycin C. Cancer Res 40: 1165-1168
2. Benthem J van, Wild CP, Vermeulen E, Engelse L den, Scherer E (1991) Immunocytochemical localization of DNA adducts induced by a single dose of N-nitroso-N-methylbenzylamine in target and non-target tissues of tumor formation in the rat. Carcinogenesis 12:1831-1837
3. Blommaert FA, Saris CP (1995) Detection of platinum-DNA adducts by 32P-postlabelling. Nucleic Acids Res 23:126-132
4. Blommaert FA, Michael C, Terheggen PMAB, Muggia FM, Kortes V, Schornagel JH, Hart AAM, Engelse L den (1993) Drug induced DNA modification in buccal cells of cancer patients receiving carboplatin and cisplatin combination chemotherapy, as determined by an immunocytochemical method: interindividual variation and correlation with disease response. Cancer Res 53:5669-5675
5. Dahl O, Mella O (1990) Hyperthermia and chemotherapeutic agents. In: Field SB, Hand JW (eds) Introduction to the practical aspects of clinical hyperthermia. Taylor and Francis, London, pp 108-133
6. Dijk JDP van, Schneider C, Os R van, Blank LECM, Gonzalez Gonzalez D (1990) Results of deep body hyperthermia with large wave guide radiators. In: Bicher HI (ed) Consensus on hyperthermia for the 1990's. Plenum, New York, pp 315-319
7. Extra JM, Espie M, Calvo F, Ferme C, Mignot L, Marty M (1990) Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 25:299-303
8. Fichtinger-Schepman AMJ, Baan RA, Luiten-Schulte A, van Dijk M, Lohman PHM (1985) Immunochemical quantitation of adducts in DNA by cis-diammine dichloroplatinum (II) and analysis of adduct related DNA-unwinding. Chem Biol Interact 55:275-288
9. Fichtinger-Schepman AMJ, Baan RA, Berends F (1989) Influence of the degree of DNA modification on the immunochemical determination of cisplatin-DNA adduct levels. Carcinogenesis 10:2367-2369
10. Fiebig HH, Berger DP, Mross K, Quiber W, Aulenbacher P, Hilgard P (1992) Lobaplatin (D-19466): preclinical drug profile and results of the phase I study. Ann Oncol 3 [Suppl 1]:338
11. Fisher GA, Hahn GM (1982) Enhancement of cisplatinum (II) diamminedichloride by hyperthermia. Natl Cancer Inst Monogr 61:255-257
12. Gerad H, Egorin MJ, Whitacre M, Van Echo DA, Aisner J (1983) Renal failure and platinum pharmacokinetics in three patients treated with cisdiamminedichloro-platinum (II) and whole body hyperthermia. Cancer Chem Pharmacol 11:162-166
13. Gietema JA, Veldhuis GJ, Guchelaar HJ, Willemse PH, Uges DR, Cats A, Boonstra H, van der Graaf WT, Sleijfer DT, de Vries EG, Mulder NH (1995) Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer. Br J Cancer 71:1302-1307
14. Haas GP, Klugo RC, Hetzel FW, Barton EE, Cerny JC (1984) The synergistic effect of hyperthermia and chemotherapy on murine transitional cell carcinoma. J Urol 132:828-833
15. Hahn GM, Li GC (1982) Interaction of hyperthermia and drugs: treatments and probes. Natl Cancer Inst Monogr 61:317
16. Issels RD, Prenninger SW, Nagele A, Boehm E, Sauer H, Jauch KW, Denecke H, Berger H (1990) Ifosfamide plus etoposide combined with regional hyperthermia in patients with locally advanced sarcomas: a phase II study. J Clin Oncol 8:1818-1829
17. Kelland LR (1993) New platinum antitumour complexes. Crit Rev Oncol Hematol 15:191-219
18. Leng M (1990) Distortions induced in double-stranded oligonucleotides by the binding of cis- or trans-diammine dichloroplatinum(II) to the d(GTG) sequence. Nucleic Acids Res 18:4395
19. Levi F, Perpoint B, Garufi C, Focan C, Chollet P, Depres-Brummer P, Zidani R, Brienza S, Itzhaki M, Iacobelli S, Kunstlinger F, Gastiaburu J, Misset JL (1993) Oxaliplatin activity against melastatic colorectal cancer. A phase II study of 5 days continuous venous infusion at circadian rhythm modulated rate. Eur J Cancer 29A:1280-1284
20. Levi FA, Zidani R, Vannetzel JM, Perpoint B, Focan C, Faggiuolo R, Chollet P, Garufi C, Itzhaki M, Dogliotti L, Iacobelli S, Adam R, Kunstlinger F, Gastiaburu J, Bismut H, Jasmin C, Misset JL (1994) Chrono-modulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Nat Cancer Inst 86:1608-1617
21. Los G, Sminia P, Wondergem J, Mutsaers PHA, Haveman J, Bokkel Huinink D ten, Smals OAG, Gonzalez Gonzalez D, McVie JG (1991) Optimisation of intraperitoneal cisplatin therapy with regional hyperthermia in rats. Eur J Cancer 27:472-477
22. Los G, Vugt MJH van, Engelse L den, Pinedo HM (1993) Effects of temperature on the interaction of cisplatin and carboplatin with cellular DNA. Biochem Pharmacol 46:1229-1237
23. Los G, Vugt MJH van, Pinedo HM (1994) Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin. Br J Cancer 69:235-241
24. Mathe G, Kidani Y, Segiguchi M, Eriguchi M, Fredi G, Peytavin G, Misset JL, Brienza, S. De Vassals F, Chenu E (1989) L-OHP, a third generation platinum complex. An experimental and clinical appraisal and preliminary comparison with cisplatin and carboplatin. Biomed Pharmacother 43:237-250
25. Mella O, Eriksen R, Dahl O, Laenum OD (1987) Acute systemic toxicity of combined cis-diamminedichloroplatinum and hyperthermia in the rat. Eur J Cancer Clin Oncol 23:365-373
26. Murthy MS, Rao LN, Khandehar JD, Scanlon EF (1987) Enhancement of the therapeutic efficacy of cisplatin by combination with diethyl dithiocarbonate and hyperthermia in a mouse model. Cancer Res 47:774-779
27. Overgaard J, Gonzalez Gonzalez D, Hulshof MCMM, Arcangeli G, Dahl O, Mella O, Brentzen SM (1995) Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. Lancet 345:540-543
28. Rice JA, Crothers DM, Pinto AL, Lippard SJ (1989) The major adduct of the antitumor drug cis-diamminedichloroplatinum (II) with DNA bends the duplex by about 40 degrees towards the major groove. Proc Natl Acad Sci USA 85:4158-4161
29. Rietbroek R, Schilthuis M, Postma A, Zum Vörde Sive Vörding P, Gonzalez Gonzalez D, Bakker A, Bakker P, Veenhof C (1995) Weekly locoregional hyperthermia and cisplatin in patients with a local recurrence of a cervical carcinoma. Proc ASCO 14:287
30. Rietbroek RC, Bakker PJM, Schilthuis MS, Postma AJ, Zum Vörde Sive Vörding PJ, Gonzalez Gonzalez D, Kurth KH, Bakker AJ, Veenhof CHN (1996) Feasibility, toxicity and preliminary results of weekly locoregional hyperthermia and cisplatin in patients with previously irradiated recurrent cervical cancer or locally advanced bladder cancer. Int J Radiat Oncol Biol Phys 34:887-893
31. Robins HI, Cohen JD, Schmitt CL, Tutsch KD, Feierabend C, Arzoomanian RZ, Alberti D, D'Oleire F, Longo W, Heiss C, Rushing D, Spriggs D (1993) Phase I clinical trial of carboplatin and 41.8 C whole-body hyperthermia in cancer patients. J Clin Oncol 11:1787-1794
32. Stege GJJ, Kampinga HH, Konings AWT (1995) Heat-induced intranuclear protein aggregation and thermal radiosensitization. Int J Radiat Biol 67:203-209
33. Stewart DJ, Benjamin RS, Luna M, Feun L, Caprioli R, Seiffert W, Loo TL (1982) Human tissue distribution of platinum after cis-diamminedichloroplatinum. Cancer Chemother Pharmacol 10:51-54
34. Tashiro T, Kawada Y, Sahurai Y, Kidani Y (1989) Antitumour activity of a new platinum complex, oxalato (trans-1-1,2-diamminocyclohexane) platinum II: new experimental data. Biomed Pharmacother 43:251-260
35. Terheggen PMAB, Dijkman R, Begg AC, Dubbelman R, Floot BGJ, Hart AAM, Engelse L den (1988) Monitoring of interaction products of cis-diamminedichloroplatinum (II) and cis-diammine(1,1-cyclo-butanedicarboxylato) platinum (II) with DNA in cells from platinum treated cancer patients. Cancer Res 48:5597-5603
36. Terheggen PMAB, Emondt JY, Floot BGJ, Dijkman R, Schrier PI, Engelse L den, Begg AC (1990) Correlation between cell killing by cis-diamminedichloroplatinum (II) in six mammalian cell lines and binding of a cis-diamminedichloroplatinum (II)-DNA antiserum. Cancer Res 50:3556-3561
37. Terheggen PMAB, Floot BGJ, Lempers ELM, Van Tellingen O, Begg AC, Engelse L den (1991) Antibodies against cisplatin-modified DNA and cisplatin-modified (di)nucleotides. Cancer Chemother Pharmacol 28:185-191
38. Urano M, Kahn J, Majima H, Gerwech LE (1990) The cytotoxic effect of cisdiammine dichloroplatinum (II) on cultured Chinese hamster ovary cells at elevated temperatures: arrhenius plot analysis. Int J Hyperthermia 6:581-590
39. Voegeli R, Schumacher W, Engel J, Respondek J, Hilgard P (1990) D-19466 a new cyclobutane-platinum complex with antitumour activity. J Cancer Res Clin Oncol 116:419-422
40. Weiss R, Michaele C (1993) New cisplatin analogues in development. A review. Drugs 46:360-377